 Updated News |
Denmark's Zealand Pharma starts Phase I diabetes drug trials
Chicago Tribune “ZP2929 may turn out to address a large unmet medical need in the field of metabolic diseases, namely better treatment of patients with diabetes and/or patients who are overweight or obese,” Chief Scientific Officer Christian Grondahl said in a statement. Zealand Pharma Advances ZP2929 Into Phase I Development for the Treatment …MarketWatch (press release) all 16 news articles » |
More details can be found at www.diabeteshowto.com
Discussion
Comments are disallowed for this post.
Comments are closed.